ICON Web & News
Search Using OECD Database
Return to Previous Page
Addition or Correction
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide
Link to Journal Abstract
Small cell lung cancer (SCLC) is the most aggressive carcinoma in thoracic oncology, unfortunately, despite chemotherapy, relapse is constant. The effect of etoposide, a major drug used against SCLC, can potentially be enhanced after its encapsulation in nanocarriers. The aim of this study was to use the technology of lipid nanocapsules (LNCs) to obtain nanocarriers with drug loadings compatible with clinical use and with an industrial process. Solubility studies with different co-solvent were first performed, then several process were developed to obtain LNCs. LNCs were then characterized (size, zeta potential, and drug loading). The best formulation called ¶-LNCs had a size of 54.1 } 2.0 nm and a zeta potential of −5.8 } 3.5 mV and a etoposide drug loading of 5.7 } 0.3 mg/g. The characteristics of this formulation were maintained after freeze drying and after a 15~ scale-up. Release studies in a media mimicking plasma composition showed that 40% of the drug was released from the LNCs after 48 h. Moreover the activity of etoposide after encapsulation was enhanced on H209 cells, IC50 was 100 ÊM and 2.5 ÊM for etoposide and etoposide LNCs respectively. Unfortunately the formulation failed to be more cytotoxic than etoposide alone on H69AR cells that are resistant to etoposide. This study showed that is was possible to obtain a new etoposide nanocarrier without the use of organic solvent, that the process is suitable for scale-up and freeze drying and finally that etoposide activity is maintained which is very promising for future treatment of SCLC.
The aim of this study was to use the technology of lipid nanocapsules (LNCs) to obtain nanocarriers with drug loadings compatible with clinical use and with an industrial process.
Peer Reviewed Journal Article
Exposure Or Hazard Target
Method Of Study
Material Analysis and Applications
Risk Exposure Group
European Journal of Pharmaceutical Sciences, 50(2): 172-180 (October 2013)
European Journal of Pharmaceutical Sciences
Saliou B, Thomas O, Lautram N, Clavreul A, Hureaux J, Urban T, Benoit JP, Lagarce F
Last updated on October 21, 2013
This work is supported in part by the Nanoscale Science and Engineering Initiative of the National Science Foundation
under NSF Award Number EEC-0118007.
Why Join Us?
Mission and Strategy
Good Nano Guide
Nano EHS Research Needs
Current Practices Survey